Columbia Flexible Capital Income Fund Boosts Bristol-Myers Squibb Stake

The fund increased its holdings in the pharmaceutical company by 12.5% during the quarter.

Published on Mar. 2, 2026

Got story updates? Submit your updates here. ›

Columbia Flexible Capital Income Fund raised its stake in Bristol-Myers Squibb Co (BMY) by 12.5%, purchasing an additional 25,000 shares to own a total of 225,000 shares. The fund's holdings in Bristol-Myers Squibb were valued at $11,070,000 as of its most recent SEC filing.

Why it matters

Bristol-Myers Squibb is a major pharmaceutical company that develops and markets drugs for various therapeutic areas. The increase in Columbia Flexible Capital Income Fund's stake suggests the fund sees value and growth potential in the company's business and pipeline.

The details

According to the fund's latest 13F filing with the SEC, it acquired 25,000 additional shares of Bristol-Myers Squibb during the quarter, raising its total position to 225,000 shares. Several other large investors also increased their stakes in the company, including Sequoia Global Value ETF, Sparkline Intangible Value ETF, Dakota Active Equity ETF, Horizon Defined Risk Fund, and Horizon Equity Premium Income Fund.

  • Columbia Flexible Capital Income Fund filed its latest 13F report on March 2, 2026.

The players

Columbia Flexible Capital Income Fund

An investment fund that focuses on generating income through a flexible capital allocation strategy.

Bristol-Myers Squibb Co

A major pharmaceutical company that discovers, develops, and markets drugs for various therapeutic areas, with a focus on immuno-oncology.

Got photos? Submit your photos here. ›

The takeaway

The increase in Columbia Flexible Capital Income Fund's stake in Bristol-Myers Squibb suggests the fund sees long-term growth potential in the pharmaceutical company's business and pipeline, which could signal positive sentiment among investors about the company's future prospects.